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Background
The neo-antigen EGFRvIII is expressed in multiple
tumor types, including high-grade astrocytomas. It is
associated with a poor prognosis and resistance to con-
ventional therapies such as chemotherapy and radiation
that are part of the standard treatment. We propose
that immunization with a live-attenuated Listeria-based
vaccine, ADU-623, expressing EGFRvIII and NY-ESO-1
will elicit robust tumor-specific immune responses cap-
able of killing EGFRvIII and/or NY-ESO-1-expressing
tumor cells and improve survival of the patients. In
addition, ADU-623 induces a potent innate immune
response that can kill transformed cells even in the
absence of neo-antigens. We designed a translational
vaccine study to evaluate the safety and immunogenicity
of this vaccine in patients with high-grade astrocytomas
after standard of care therapy or at progression.
Methods
Patients with a pathologic diagnosis of WHO Grade III/
IV astrocytic tumors that have completed standard of
care external beam radiation therapy and concurrent
temozolomide followed by adjuvant temozolomide or
with radiographic evidence of progression following
standard of care radiation and chemotherapy treatment,
including those who have gone on to a second surgical
resection are eligible. Patients are enrolled and assigned
consecutively to one of the following ADU-623 dose level
cohorts: Cohort 1 3x107 cfu, Cohort 2 3x108 cfu, or
Cohort 3 1x109 cfu, each administered IV on Days 0, 21,
42 and 63. Adverse events are monitored throughout the
treatment and patients are followed for up to 24 months.
Patients are currently accruing to Cohort 3. The primary
objective is to determine the maximum tolerated dose
and characterize the safety profile of ADU-623 in patients
with treated and recurrent WHO Grade III/IV astrocyto-
mas. Secondary objectives include progression free survi-
val, time to progression and overall survival rates
in patients vaccinated with ADU-623. Exploratory studies
of EGFRvIII-, NY-ESO-1-, vector-specific and innate
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